These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28635863)

  • 1. [Modern approaches to treatment of psychosis in Parkinson's disease].
    Cozac VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):103-109. PubMed ID: 28635863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological interventions for psychosis in Parkinson's disease patients.
    Friedman JH
    Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
    Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
    Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
    Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
    Hubbard D; Hacksell U; McFarland K
    Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
    Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
    J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease.
    Parsa MA; Bastani B
    J Neuropsychiatry Clin Neurosci; 1998; 10(2):216-9. PubMed ID: 9608412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin as treatment for Parkinson's disease psychosis.
    Fox SH
    Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.
    Frieling H; Hillemacher T; Ziegenbein M; Neundörfer B; Bleich S
    Eur Neuropsychopharmacol; 2007 Feb; 17(3):165-71. PubMed ID: 17070675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
    Moreno GM; Gandhi R; Lessig SL; Wright B; Litvan I; Nahab FB
    Neurology; 2018 Oct; 91(17):797-799. PubMed ID: 30258020
    [No Abstract]   [Full Text] [Related]  

  • 15. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
    Sellers J; Darby RR; Farooque A; Claassen DO
    Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of psychotic aspects of Parkinson's disease.
    Juncos JL
    J Clin Psychiatry; 1999; 60 Suppl 8():42-53. PubMed ID: 10335670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
    Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096
    [No Abstract]   [Full Text] [Related]  

  • 19. Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
    Citrome L
    CNS Spectr; 2018 Dec; 23(6):355-357. PubMed ID: 30588903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Understanding of Psychosis in Parkinson's Disease.
    Ojo OO; Fernandez HH
    Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.